Bronte Capital Management Pty Ltd.
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS OPT | REGN | $144.2M | 162,618 | -2.98pp | 23q | -5.9%-$9.0M | |
| ALPHABET INC | GOOGL | $109.1M | 305,165 | +0.85pp | 31q | -20.0%-$27.3M | |
| INTERACTIVE BROKERS GROUP IN | IBKR | $76.9M | 883,526 | -0.25pp | 31q | -31.1%-$34.7M | |
| VISA INC-CLASS A SHARES UNVERIFIED ID | $75.5M | 219,914 | +0.94pp | 12q | -8.1%-$6.7M | ||
| BERKSHIRE HATHAWAY INC DEL | BRKB | $73.0M | 145,847 | +0.48pp | 31q | -5.9%-$4.6M | |
| AMAZON COM INC | AMZN | $62.3M | 261,433 | +0.80pp | 14q | -8.5%-$5.8M | |
| PHILIP MORRIS INTL INC | PM | $54.3M | 300,176 | +0.25pp | 20q | -12.0%-$7.4M | |
| CORTEVA INC | CTVA | $38.7M | 456,656 | -0.01pp | 28q | -9.2%-$3.9M | |
| CAPITAL ONE FINL CORP | COF | $34.8M | 173,523 | +0.35pp | 5q | -7.4%-$2.8M | |
| DISNEY WALT CO | DIS | $34.7M | 360,243 | +1.95pp | 2q | +94.0%+$16.8M | |
| FIRST CTZNS BANCSHARES INC D | FCNCA | $29.5M | 14,179 | +0.09pp | 14q | -14.0%-$4.8M | |
| BBB FOODS INC | TBBB | $22.2M | 533,151 | +0.68pp | 3q | +9.4%+$1.9M | |
| AURORA INNOVATION INC | AUR | $14.9M | 2,186,821 | +0.66pp | 2q | -5.7%-$899.7K | |
| VANECK ETF TRUST UNVERIFIED ID | $14.5M | 191,580 | -0.34pp | 12q | -7.9%-$1.2M | ||
| SOTERA HEALTH CO UNVERIFIED ID | $14.1M | 797,138 | +0.32pp | 14q | -5.5%-$826.7K | ||
| NEKTAR THERAPEUTICS | NKTR | $13.9M | 198,434 | -1.37pp | 2q | HELD | |
| GRAHAM HLDGS CO | GHC | $13.1M | 11,454 | +0.07pp | 24q | -10.4%-$1.5M | |
| ISHARES TR | IBB | $12.5M | 65,807 | +0.19pp | 17q | -5.0%-$657.7K | |
| BROWN FORMAN CORP | BFB | $12.4M | 464,313 | - | new | NEW | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $10.7M | 35,384 | -0.08pp | 4q | -5.0%-$560.2K | |
| SOCIEDAD QUIMICA Y MINERA DE | SQM | $8.6M | 116,308 | -0.06pp | 19q | -5.0%-$452.5K | |
| GLOBAL E ONLINE LTD | GLBE | $7.9M | 227,644 | +0.20pp | 2q | +6.8%+$505.0K | |
| NEWMONT CORP | NEM | $6.5M | 69,494 | -0.11pp | 5q | -7.8%-$552.4K | |
| BARRICK MNG CORP | B | $5.4M | 146,359 | -0.06pp | 5q | -7.8%-$454.8K | |
| LIVERAMP HLDGS INC | RAMP | $4.8M | 128,348 | -0.07pp | 11q | -42.5%-$3.6M | |
| HERBALIFE LTD | HLF | $4.3M | 323,386 | -0.91pp | 31q | -65.6%-$8.1M | |
| REVOLUTION MEDICINES INC | RVMD | $3.5M | 18,780 | - | new | NEW | |
| TURNING PT BRANDS INC | TPB | $3.5M | 40,721 | flat | 3q | -5.0%-$181.3K | |
| ISHARES TR | IJR | $3.4M | 23,004 | - | new | NEW | |
| BATH & BODY WORKS INC | BBWI | $3.3M | 143,800 | +0.07pp | 20q | -7.5%-$270.8K | |
| MONDELEZ INTL INC | MDLZ | $3.1M | 53,234 | +0.01pp | 21q | -4.9%-$158.5K | |
| RISKIFIED LTD | RSKD | $3.0M | 588,251 | +0.13pp | 16q | +20.4%+$502.8K | |
| BROWN FORMAN CORP | BFA | $2.6M | 95,365 | +0.01pp | 2q | -5.0%-$136.5K | |
| TYLER TECHNOLOGIES INC | TYL | $2.4M | 8,302 | - | new | NEW | |
| VANECK ETF TRUST UNVERIFIED ID | $2.4M | 24,568 | -0.06pp | 12q | -7.5%-$196.3K | ||
| PAYLOCITY HLDG CORP | PCTY | $1.9M | 17,874 | -0.19pp | 2q | -51.2%-$2.0M | |
| NICE LTD | NICE | $1.5M | 16,396 | -0.03pp | 3q | -4.1%-$63.1K | |
| UNIVERSAL DISPLAY CORP | OLED | $889.2K | 10,269 | -0.01pp | 3q | -7.7%-$73.8K | |
| VERISK ANALYTICS INC | VRSK | $481.5K | 2,682 | flat | 2q | -7.6%-$39.5K | |
| ENOVIX CORPORATION | ENVX | $92.9K | 41,765 | flat | 4q | +261.6%+$67.2K | |
| TREACE MED CONCEPTS INC | TMCI | $62.0K | 15,577 | - | new | NEW | |
| FATE THERAPEUTICS INC | FATE | $58.7K | 21,740 | flat | 3q | -4.9%-$3.0K | |
| AN2 THERAPEUTICS INC | ANTX | $52.7K | 10,895 | - | new | NEW | |
| C4 THERAPEUTICS INC | CCCC | $48.3K | 10,349 | flat | 3q | +3.1%+$1.5K | |
| ALX ONCOLOGY HLDGS INC | ALXO | $37.5K | 18,095 | - | new | NEW | |
| BLEND LABS INC | BLND | $32.9K | 19,247 | - | new | NEW | |
| PEPGEN INC | PEPG | $32.0K | 17,776 | - | new | NEW | |
| COMMERCE.COM INC | CMRC | $30.4K | 10,278 | - | new | NEW | |
| PACIFIC BIOSCIENCES CALIF IN | PACB | $30.0K | 17,881 | - | new | NEW | |
| ACUMEN PHARMACEUTICALS INC | ABOS | $28.6K | 10,716 | - | new | NEW | |
| SEER INC | SEER | $25.1K | 15,109 | - | new | NEW | |
| ALECTOR INC | ALEC | $23.6K | 11,758 | flat | 3q | -39.0%-$15.1K | |
| NOVABRIDGE BIOSCIENCES | NBP | $21.8K | 11,192 | - | new | NEW | |
| COHERUS ONCOLOGY INC | CHRS | $21.4K | 15,262 | flat | 3q | -20.8%-$5.6K | |
| MILESTONE PHARMACEUTICALS IN | MIST | $19.3K | 14,390 | flat | 3q | +38.2%+$5.3K | |
| GOSSAMER BIO INC | GOSS | $11.2K | 67,754 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $172.6M | 18.5% |
| Software & IT Services | $143.0M | 15.4% |
| Retail & Consumer | $87.9M | 9.4% |
| Capital Markets | $76.9M | 8.3% |
| Food, Drink & Tobacco | $75.8M | 8.1% |
| Insurance | $73.0M | 7.8% |
| Banks & Lending | $64.3M | 6.9% |
| Agriculture | $38.7M | 4.2% |
| Telecom & Media | $34.7M | 3.7% |
| Mining & Metals | $20.5M | 2.2% |
| Business Services | $16.0M | 1.7% |
| Other sectors | $5.3M | 0.6% |
| Not classified | $122.4M | 13.1% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $931.1M | 56 | 15 | 7 | 33 | 10 | 75.5% | 36 |
| Q1 2026 | $1.0B | 51 | 9 | 6 | 25 | 1 | 74.5% | 27 |
| Q4 2025 | $1.0B | 43 | 16 | 2 | 18 | 3 | 81.5% | 34 |
| Q3 2025 | $1.1B | 30 | 4 | 0 | 26 | 1 | 76.2% | 36 |
| Q2 2025 | $1.3B | 27 | 3 | 21 | 3 | 2 | 78.7% | 43 |
| Q1 2025 | $1.2B | 26 | 2 | 3 | 21 | 0 | 79.4% | 44 |
| Q4 2024 | $1.3B | 24 | 0 | 3 | 21 | 1 | 81.6% | 41 |
| Q3 2024 | $1.2B | 25 | 0 | 4 | 8 | 3 | 79.4% | 36 |
| Q2 2024 | $1.3B | 28 | 0 | 4 | 24 | 2 | 76.6% | 38 |
| Q1 2024 | $1.2B | 30 | 2 | 10 | 13 | 2 | 72.0% | 43 |
| Q4 2023 | $1.1B | 30 | 3 | 9 | 17 | 1 | 73.9% | 38 |
| Q3 2023 | $992.8M | 28 | 4 | 14 | 5 | 8 | 75.4% | 37 |
| Q2 2023 | $1.0B | 32 | 3 | 26 | 1 | 1 | 70.6% | 39 |
| Q1 2023 | $861.9M | 30 | 4 | 6 | 20 | 1 | 78.7% | 42 |
| Q4 2022 | $792.6K | 27 | 0 | 4 | 22 | 1 | 79.0% | 45 |
| Q3 2022 | $802.9M | 28 | 1 | 8 | 11 | 5 | 79.7% | 34 |
| Q2 2022 | $872.5M | 32 | 2 | 17 | 7 | 1 | 72.8% | 39 |
| Q1 2022 | $1.2B | 31 | 5 | 18 | 5 | 2 | 83.9% | 43 |
| Q4 2021 | $1.5B | 28 | 2 | 8 | 12 | 1 | 87.3% | 41 |
| Q3 2021 | $1.4B | 27 | 6 | 6 | 2 | 0 | 88.7% | 40 |
| Q2 2021 | $1.4B | 21 | 4 | 4 | 3 | 0 | 91.0% | 40 |
| Q1 2021 | $881.6M | 17 | 2 | 7 | 6 | 0 | 89.3% | 13 |
| Q4 2020 | $632.9M | 15 | 2 | 1 | 7 | 0 | 90.7% | 34 |
| Q3 2020 | $567.9M | 13 | 4 | 4 | 3 | 2 | 96.1% | 77 |
| Q2 2020 | $570.1M | 11 | 0 | 7 | 3 | 1 | 98.7% | 42 |
| Q1 2020 | $610.8M | 12 | 4 | 7 | 0 | 1 | 97.8% | 38 |
| Q4 2019 | $515.5M | 9 | 0 | 6 | 1 | 3 | 100.0% | 29 |
| Q3 2019 | $361.6M | 12 | 1 | 8 | 1 | 0 | 97.9% | 39 |
| Q2 2019 | $280.6M | 11 | 3 | 2 | 2 | 3 | 99.9% | 44 |
| Q1 2019 | $266.5M | 11 | 2 | 5 | 0 | 1 | 99.6% | 40 |
| Q4 2018 | $250.7M | 10 | 0 | 0 | 0 | 0 | 100.0% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.